King's Research Portal

DOI:

[10.1016/j.coph.2018.07.011](https://doi.org/10.1016/j.coph.2018.07.011)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Rackham, C. L., & Jones, P. M. (2018). Potential of mesenchymal stromal cells for improving islet transplantation outcomes. *Current Opinion in Pharmacology*, 43, 34-39.

<https://doi.org/10.1016/j.coph.2018.07.011>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Potential of mesenchymal stromal cells for improving islet transplantation outcomes

Chloe L Rackham and Peter M Jones

Department of Diabetes, School of Life Course Sciences, King's College London, Guy's Campus,
London SE1 1UL

Corresponding author: Chloe L Rackham

Department of Diabetes,
School of Life Course Sciences,
Faculty of Life Sciences and Medicine
Guy's Campus
King's College London,
London SE1 1UL, UK

E-mail: chloe.rackham@kcl.ac.uk

Word count: 2142

Abstract

Allogeneic islet transplantation as a therapy for Type 1 Diabetes (T1D) is restricted by the limited availability of donor islets, loss of functional islets during pre-transplantation culture *in vitro* and further extensive loss during the immediate post-transplantation period when islet function and survival is compromised by the hypoxic, inflammatory host environment. In the longer term pathogenic T cell responses drive autoimmunity and chronic allograft rejection. Experimental studies have demonstrated that Mesenchymal Stromal Cells (MSCs) have significant potential to improve the outcomes of clinical islet transplantation. This review explores the potential for MSCs and their 'secretome' to influence donor islet cell function and survival, as well as the host niche. We discuss the possibility of harnessing the therapeutic benefits of MSCs in a cell-free strategy to offer a well-defined, cell-free approach to improve the outcomes of clinical islet transplantation.

Introduction

Islet transplantation

Type 1 diabetes mellitus (T1DM) is an autoimmune disorder in which insulin-secreting pancreatic β -cells are selectively destroyed. The consequent insulin deficiency results in dysregulation of metabolic control with hyperglycemia, hyperlipidemia and ketosis leading to a fatal outcome. People with T1DM have been treated by the administration of exogenous insulin since the first successful isolation of biologically active insulin in 1921. However, insulin therapy treats the symptoms of T1DM rather than offering a cure, and it has become clear over the decades that exogenous insulin often fails to maintain tight glycaemic control, and that the subsequent hyperglycemic excursions are responsible for the progressive development of a range of devastating side effects known as “secondary complications” [1]. Replacement of the damaged β -cells offers the potential for restoring physiological glycaemic control and thus avoiding the development of secondary complications. However, pancreas transplantation is surgically invasive and associated with significant co-morbidity [2]. An alternative is to transplant only the endocrine component of the pancreas - the islets of Langerhans- which comprise 2-3 % of the total pancreas, and which can be isolated from the intact pancreas by collagenase digestion. Islet transplantation first became a viable therapeutic option with the publication of the landmark “Edmonton Protocol” in 2000 [3], which stimulated human islet transplantation programmes around the world, such that over 1,500 people with T1DM have now received islet grafts in 40 centres globally (<https://citregistry.org/content/citr-9th-annual-report>). Islet transplantation is a safe procedure with little or no co-morbidity [4] and the clinical outcomes have improved year-on-year [4,5]. Recent figures suggest that approximately 50 % of graft recipients remain insulin independent at 5 years and more, making islet transplantation as clinically effective as whole pancreas transplantation [6]. However, the wider adoption of islet transplantation as a therapeutic option is currently limited by a shortage of tissue donors and much effort is currently directed at generating functionally-competent substitutes for primary human islets to expand the available pool of graft material.

Islet β -cells are metabolically active and use glucose metabolism and ATP generation to maintain appropriate rates of insulin secretion for the prevailing extracellular glucose concentrations. Islets deteriorate rapidly during and after their isolation [7], losing 20-50 % of the β -cell mass within 24h of culture *in vitro*. The loss of β -cell function continues during the immediate post-transplantation period (24-72h) when up to 70 % of the graft function is lost because of deleterious responses of the transplanted β -cells to the hypoxic, inflammatory, immunogenic host environment [8]. Strategies which improve the functional survival of islets both before and after transplantation will improve the

outcome of individual grafts and enable the limited pool of donor islets to treat many more people with T1DM. One emerging strategy is the use of mesenchymal stromal cells (MSCs) to take advantage of their anti-inflammatory, immunoregulatory, angiogenic and regenerative properties.

Mesenchymal stromal cells and islet transplantation

MSCs are multipotent adult stromal progenitor cells located in the perivascular niche of most adult tissues, where they are involved in regeneration and repair in response to tissue ageing or damage. Importantly, MSCs can be isolated from their host tissues and maintained and expanded *in vitro*. There is no single specific marker for identifying MSCs, so the International Society for Cellular Therapy has specified three essential criteria to define cells as MSCs. First, cells must be plastic-adherent when maintained in standard culture conditions. Second, ≥ 95 % of cells must express CD105, CD73 and CD90 but not express the hematopoietic markers CD45, CD34, CD14 or CD11b, CD79 α or CD19 and HLA class II. Finally, MSCs must be capable of differentiation into osteoblasts, adipocytes and chondroblasts *in vitro* [9].

There is accumulating evidence that MSCs can improve the outcomes of islet transplantation in experimental models. Thus, co-administration of MSCs improved islet graft function in syngeneic [11-12, 21], allogenic [13-16] and humanised mouse models [17] and in non-human primate models [18] of islet transplantation. A range of *in vitro* and *in vivo* studies suggest that MSCs exert direct effects on the islet β -cells to improve their post-transplantation function and survival, and also influence the host environment to suppress inflammatory innate immune responses [19] and T-cell-dependent acquired immunity [20], and to enhance revascularisation of the graft [11-13,21].

Influencing the host environment

Isolated islets are metabolically fragile because of the stresses (mechanical, enzymatic), loss of extracellular matrix (ECM) [22] and ischaemia associated with the isolation process. These fragile islets are transplanted into a hostile inflammatory environment leading to further β -cell death [23]. The clinically-preferred route for graft delivery via the hepatic portal vein has the advantages of being simple, minimally-invasive and targeting insulin to the liver, but intravascular delivery triggers the instant blood mediated inflammatory response (IBMIR). This leads to thrombus formation around the islets and the initiation of an inflammatory cascade, both of which are deleterious to the islet graft [24]. In the longer term, auto- and allo-reactive T cell responses to transplanted islets contribute to graft attrition [20], and the metabolically-active β -cells are susceptible to anoxia during the revascularisation process [25].

Modulating the host immune response

MSCs can influence cells of the innate and adaptive immune systems and their co-transplantation at extrahepatic sites creates an immunosuppressive niche [14]. For example, MSCs influence macrophage phenotype by inducing a shift from pro- (M1) to anti-inflammatory (M2) macrophages (reviewed in [19]), which reduces graft neutrophil infiltration and inflammation during the immediate post-transplantation period. MSCs also have the potential to intercept the priming and amplification of autoreactive T cells. Thus, in T1DM MSCs can drive monocyte-derived dendritic cells (DCs) toward an immature, IL-10 producing regulatory phenotype via mechanisms dependent on IL-6, TGF- β and prostaglandin-E2 (PGE2) production [26]. More chronically, MSCs or multipotent adult progenitor cells (MAPCs [27]; off-the shelf clinical grade MSCs) influence cells of the acquired immune system to suppress pathogenic T cell proliferation [13,28-31] and the production of proinflammatory cytokines, whilst favouring a more protective regulatory T cell response and altering the Th1/Th2/Th17 cytokine balance [15,20,32,33]. MSC co-transplantation prevents the Th17 immune response in a mouse allogeneic model of extrahepatic islet transplantation, but this effect was only observed when MSCs were co-delivered with the islets beneath the kidney capsule to create a local immune-privileged site, and not when the MSCs were injected systemically (intravenous) [14]. This has implications for delivering human islets via the clinically-preferred intraportal route because this will not facilitate the co-engraftment of islets and MSCs since their different sizes (~100 μ m and ~10 μ m diameter, respectively) will ensure that they lodge in different compartments of the hepatic microcirculation.

An alternative strategy is to identify the key MSC-derived soluble mediators which mediate the beneficial effects and use these in a “cell-free” therapeutic capacity. MSC-derived exosomes [26,34] and secreted factors have been shown to contribute to the immunosuppressive properties of MSCs (reviewed in [35]), including matrix metalloprotease 2 (MMP2), MMP9 [28], PGE2 [36,37], IDO [32], HGF, PDL-1, TGF- β , IL-4 and TSG-6. In addition, we have recently identified a range of MSC-secreted ligands for islet G-protein-coupled receptors (GPCRs; [38,39], including Annexin A1 (ANXA1) and chemokine (C-X-C motif) ligand (CXCL) 12, which can influence T-cell mediated immune responses. CXCL12 repels cytotoxic CD8⁺ T cells from infiltrating the islet graft whilst attracting protective regulatory T cells, and coating islets with CXCL12 delays allogeneic graft rejection [40]. Systemic administration of ANXA1 delays pro-inflammatory Th17 cell-mediated progression of autoimmune uveitis [41,42], a mechanism that may also be important in reducing Th17-mediated β -cell apoptosis in autoimmune T1DM and clinical islet transplantation.

Improving revascularisation

Transplanted islets are avascular during the immediate post transplantation period exposing β -cells to a hypoxic microenvironment [25] which can lead to ischaemic cell death, so enhancing graft revascularisation should improve transplantation outcomes. Numerous studies have demonstrated that co-transplantation of MSCs [11-13,21] or MAPCs [27] improves islet revascularisation via a range of pro-angiogenic factors [12,43]. For example, Cunha and colleagues [27] identified angiogenic factors expressed by MAPCs, including vascular endothelial cell growth factor (VEGF-A, -C, and -D), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and IL-8, which are likely to contribute to enhanced revascularisation. Wnt signalling in MSCs promotes the secretion of pro-angiogenic proteins as well as extracellular matrix proteins that generate a niche for islet regeneration [44], and MSCs secrete Wnt4 and Wnt5a [38]. However, these factors have opposing effects on islet endothelial cell survival (EC) with Wnt4 conferring protective effects and Wnt5 detrimental effects [45]. Notably, the protective effects of Wnt4 were also associated with reduced expression of vascular adhesion molecule 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1), indicative of reduced inflammation in the ECs. Identifying and delivering MSC-derived molecules which enhance islet graft revascularisation should improve β -cell survival during the crucial immediate post-transplantation period.

Improving graft functional survival

Several experimental studies have shown that MSCs maintain functional β -cell mass during culture *in vitro* [46-48], with associated improvements in islet graft function *in vivo* [46,47], and it is now well established that MSCs have direct effects on β -cells to enhance their insulin secretory capacity [12,46-49] and protect them from cytokine-induced apoptosis [50]. Direct cell-cell contact plays a role in the capacity of MSCs to promote insulin secretory function [46,47,51], with N-cadherin interactions maintaining the function of encapsulated islets in diabetic mice [51]. It is well established that ECM components exert beneficial effects on the function and viability of islets. Both mouse and human MSCs lay down an ECM consisting mainly of collagen 3A1 and 4A1 *in vitro* [39,52] and MSC-derived ECM enhances islet insulin secretory function *in vitro* [39]. The precise mechanism through which islet-ECM interactions enhance islet insulin function is unclear but integrin receptors are likely to play a role. Integrins are a large family of $\alpha\beta$ heterodimeric transmembrane glycoproteins which maintain cell adhesion and provide bidirectional signal transduction across the islet cell membrane. Islet-integrin-ECM binding has been linked to the activation of signalling cascade components implicated in improved islet function and survival, such as PKB/Akt and Erk1/2 [53]. More recently, it has been

shown that collagen 3, a common component of ECM, potentiates insulin secretion by activating β -cell GPCR 56 [54], which is the most abundantly expressed GPCR in mouse and human islets [55].

Soluble secretory products also play important roles in the beneficial effects of MSCs on islet function. [38]. Hypoxic preconditioning of human adipose-derived MSCs has been shown to alter their secretome, with associated improvements in human islet function and protection from cytokine-induced apoptosis [56]. We have demonstrated recently that pre-culturing islets with ANXA1 *in vitro* improved the functional quality of mouse and human islets [38,39] and the outcomes of subsequent experimental islet transplantation [38]. We have recently extended these studies to demonstrate that a defined 'cocktail' of MSC-derived molecules is more effective than ANXA1 alone. Thus, pre-culturing mouse islets with a cocktail of three MSC secretory products – ANXA1, SDF-1 and complement component C3a - induced persistent improvements in insulin secretion and protection from cytokine-induced apoptosis for up to 72h after the pre-incubation period (Rackham et al., under review), which covers the immediate post-transplantation period when graft survival is compromised [23]. These *in vitro* observations correlate with improved *in vivo* function of islets which were pre-cultured with the cocktail before implantation (Rackham et al., under review). Recent studies suggest that the persistent effects of ANXA1, following its removal from the culture media, may be due to the up-regulation of the formyl peptide receptor (FPR)2/ALX, PI3K and subsequent downstream pathways including activation of pro-survival Akt [57]. Restoration of Akt signalling in the heart and kidney has also been demonstrated following treatment with recombinant ANXA1, with associated reductions in the development of both cardiac and renal dysfunction, which is typically associated with the underlying diabetic phenotype [58]. Thus, MSCs and their 'secretome' maintain functional β -cell mass *in vitro* and support islet functional survival after transplantation, with the additional potential to reduce the development and progression of secondary microvascular complications.

Conclusion

There is convincing experimental evidence that MSCs improve the outcomes of experimental islet transplantation and therefore have the potential to improve human islet transplantation as a therapy for T1DM. It has become evident that MSCs secrete molecules which have beneficial effects on the islet graft and/or on the host environment. Defining a cocktail of MSC secretory factors which improves the functional survival of donor islets, enhances their revascularisation and reduces inflammatory and pathogenic T cell responses raises the possibility of harnessing the therapeutic benefits of MSCs in a cell-free strategy [38,59], avoiding the logistical, safety and regulatory concerns of including MSCs in clinical islet transplantation protocols. Schematic 1 shows three potential sites

for therapeutic intervention: pre-treating the donor islets with a cocktail of factors to improve subsequent functional survival; short-term co-delivery of defined factors to the site of islet engraftment, either by pre-coating the islets [40] or by incorporating the factors into polymeric islet nanocoatings [60]; and longer-term systemic administration of chosen factors. We suggest that, in combination, these approaches offer a well-defined, cell-free approach to improve the outcomes of clinical islet transplantation.

Conflicts of interest statement

Nothing declared

Acknowledgements

Our work on MSCs and islet function is supported by Diabetes UK (Grant number 15/0005146 to P.M.J and C.L.R) and a David Matthews Research Fellowship from the Diabetes Research and Wellness Foundation (CR).

Figure Legend

Figure 1: Schematic for proposed delivery of MSC-derived secretory products during the islet transplantation procedure. Based on experimental studies, we propose a tripartite strategy for using MSC secretory products to improve islet transplantation outcomes.

1. Preculture islets *in vitro* with a defined cocktail of soluble MSC-derived secretory products for 24-48h before transplantation to enhance subsequent graft function.
2. Co-delivery of defined MSC-derived secretory products with the islet graft will ensure localised effects on graft and host niche *in vivo*, during the early post-transplantation period (7-14 days post-transplantation).
3. Systemic delivery of MSC-derived secretory products will enable sustained effects of MSC-biotherapeutics *in vivo*.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

*** of special interest**

**** of outstanding interest**

1. Adeshara KA, Diwan AG, Tupe RS: **Diabetes and complications: Cellular signaling pathways, current understanding and targeted therapies.** *Curr Drug Targets* (2016) **17**(11):1309-1328.
2. Dholakia S, Royston E, Quiroga I, Sinha S, Reddy S, Gilbert J, Friend PJ: **The rise and potential fall of pancreas transplantation.** *Br Med Bull* (2017) **124**(1):171-179.
3. Shapiro AM, Lakey JR, Ryan EA, Korbitt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: **Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.** *N Engl J Med* (2000) **343**(4):230-238.
4. Shapiro AM, Pokrywczynska M, Ricordi C: **Clinical pancreatic islet transplantation.** *Nat Rev Endocrinol* (2017) **13**(5):268-277.

****This review discusses current progress and obstacles that limit the more widespread application of islet transplantation.**

5. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, Pattou F *et al*: **Improvement in outcomes of clinical islet transplantation: 1999-2010.** *Diabetes Care* (2012) **35**(7):1436-1445.
6. Gruessner AC: **2011 update on pancreas transplantation: Comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the international pancreas transplant registry (iptr).** *Rev Diabet Stud* (2011) **8**(1):6-16.
7. Kin T, Senior P, O'Gorman D, Richer B, Salam A, Shapiro AM: **Risk factors for islet loss during culture prior to transplantation.** *Transpl Int* (2008) **21**(11):1029-1035.
8. Citro A, Cantarelli E, Piemonti L: **Anti-inflammatory strategies to enhance islet engraftment and survival.** *Curr Diab Rep* (2013) **13**(5):733-744.
9. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: **Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement.** *Cytotherapy* (2006) **8**(4):315-317.
10. Rackham CL, Jones PM, King AJ: **Maintenance of islet morphology is beneficial for transplantation outcome in diabetic mice.** *PLoS One* (2013) **8**(2):e57844.

11. Borg DJ, Weigelt M, Wilhelm C, Gerlach M, Bickle M, Speier S, Bonifacio E, Hommel A: **Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngeneic mouse model.** *Diabetologia* (2014) **57**(3):522-531.
12. Ito T, Itakura S, Todorov I, Rawson J, Asari S, Shintaku J, Nair I, Ferreri K, Kandeel F, Mullen Y: **Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function.** *Transplantation* (2010) **89**(12):1438-1445.
13. Jacobson S, Kumagai-Braesch M, Tibell A, Svensson M, Flodstrom-Tullberg M: **Co-transplantation of stromal cells interferes with the rejection of allogeneic islet grafts.** *Annals of the New York Academy of Sciences* (2008) **1150**(213-216).
14. Moufida Ben N, Andrea V, James A, Liye L, Eirini K, Francesca DA, Sara T, Domenico C, Roberto B, Alessandro V-V, Vera U *et al*: **Co-transplantation of autologous mscs delays islet allograft rejection and generates a local immunoprivileged site.** *Acta Diabetologica* (2015).
15. Mohammadi Ayenehdeh J, Niknam B, Rasouli S, Hashemi SM, Rahavi H, Rezaei N, Soleimani M, Liaeiha A, Niknam MH, Tajik N: **Immunomodulatory and protective effects of adipose tissue-derived mesenchymal stem cells in an allograft islet composite transplantation for experimental autoimmune type 1 diabetes.** *Immunol Lett* (2017) **188**(21-31).
16. Solari MG, Srinivasan S, Boumaza I, Unadkat J, Harb G, Garcia-Ocana A, Feili-Hariri M: **Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia.** *J Autoimmun* (2009) **32**(2):116-124.
17. Wu H, Wen D, Mahato RI: **Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model.** *Mol Ther* (2013) **21**(9):1778-1786.
18. Dora MB, Melissa AW, Dongmei H, Gary K, Norman MK, Over C, Julie AK, Roger WW, David HOC, Amelia MB, Norma SK: **Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates.** *Diabetes* (2010) **59**(10):2558-2568.
19. Le Blanc K, Davies LC: **Mesenchymal stromal cells and the innate immune response.** *Immunol Lett* (2015) **168**(2):140-146.
20. Reading JL, Sabbah S, Busch S, Tree TI: **Mesenchymal stromal cells as a means of controlling pathological t-cell responses in allogeneic islet transplantation.** *Curr Opin Organ Transplant* (2013) **18**(1):59-64.
21. Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJ: **Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice.** *Diabetologia* (2011) **54**(5):1127-1135.

22. Wang RN, Rosenberg L: **Maintenance of beta-cell function and survival following islet isolation requires re-establishment of the islet-matrix relationship.** *J Endocrinol* (1999) **163**(2):181-190.
23. Davalli AM, Scaglia L, Zangen DH, Hollister J, Bonner-Weir S, Weir GC: **Vulnerability of islets in the immediate posttransplantation period. Dynamic changes in structure and function.** *Diabetes* (1996) **45**(9):1161-1167.
24. Nilsson B, Ekdahl KN, Korsgren O: **Control of instant blood-mediated inflammatory reaction to improve islets of langerhans engraftment.** *Curr Opin Organ Transplant* (2011) **16**(6):620-626.
25. Miao G, Ostrowski RP, Mace J, Hough J, Hopper A, Peverini R, Chinnock R, Zhang J, Hathout E: **Dynamic production of hypoxia-inducible factor-1alpha in early transplanted islets.** *Am J Transplant* (2006) **6**(11):2636-2643.
26. Favaro E, Carpanetto A, Caorsi C, Giovarelli M, Angelini C, Cavallo-Perin P, Tetta C, Camussi G, Zanone MM: **Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients.** *Diabetologia* (2016) **59**(2):325-333.
27. Cunha JP, Leuckx G, Sterkendries P, Korf H, Bomfim-Ferreira G, Overbergh L, Vaes B, Heimberg H, Gysemans C, Mathieu C: **Human multipotent adult progenitor cells enhance islet function and revascularisation when co-transplanted as a composite pellet in a mouse model of diabetes.** *Diabetologia* (2017) **60**(1):134-142.
28. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ: **Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9.** *Diabetes* (2009) **58**(8):1797-1806.
29. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN *et al*: **Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes.** *J Immunol* (2009) **183**(2):993-1004.
30. Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, Eljaafari A, Thivolet C: **Mesenchymal stem cells protect nod mice from diabetes by inducing regulatory t cells.** *Diabetologia* (2009) **52**(7):1391-1399.
31. Duprez IR, Johansson U, Nilsson B, Korsgren O, Magnusson PU: **Preparatory studies of composite mesenchymal stem cell islets for application in intraportal islet transplantation.** *Ups J Med Sci* (2011) **116**(1):8-17.
32. Reading JL, Yang JH, Sabbah S, Skowera A, Knight RR, Pinxteren J, Vaes B, Allsopp T, Ting AE, Busch S, Raber A *et al*: **Clinical-grade multipotent adult progenitor cells durably control pathogenic t cell responses in human models of transplantation and autoimmunity.** *J Immunol* (2013) **190**(9):4542-4552.

33. Ezquer F, Ezquer M, Contador D, Ricca M, Simon V, Conget P: **The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore th1/th2 balance and to modify the pancreatic microenvironment.** *Stem Cells* (2012) **30**(8):1664-1674.
 34. Wen D, Peng Y, Liu D, Weizmann Y, Mahato RI: **Mesenchymal stem cell and derived exosome as small rna carrier and immunomodulator to improve islet transplantation.** *J Control Release* (2016) **238**:166-175.
 35. Xv J, Ming Q, Wang X, Zhang W, Li Z, Wang S, Li Y, Li L: **Mesenchymal stem cells moderate immune response of type 1 diabetes.** *Cell Tissue Res* (2017) **368**(2):239-248.
 36. Carty F, Corbett JM, Cunha JPMC, Reading JL, Tree TIM, Ting AE, Stubblefield SR, English K: **Multipotent adult progenitor cells suppress t cell activation in.** *Front Immunol* (2018) **9**:645.
 37. Reading JL, Vaes B, Hull C, Sabbah S, Hayday T, Wang NS, DiPiero A, Lehman NA, Taggart JM, Carty F, English K *et al*: **Suppression of il-7-dependent effector t-cell expansion by multipotent adult progenitor cells and pge2.** *Mol Ther* (2015) **23**(11):1783-1793.
 38. Rackham CL, Vargas AE, Hawkes RG, Amisten S, Persaud SJ, Austin AL, King AJ, Jones PM: **Annexin a1 is a key modulator of mesenchymal stromal cell-mediated improvements in islet function.** *Diabetes* (2016) **65**(1):129-139.
- ** This study demonstrates that using MSC-derived secretory products mimics the *in vitro* and *in vivo* effects of MSCs on islet function.
39. Arzouni AA, Vargas-Seymour A, Rackham CL, Dhadda P, Huang GC, Choudhary P, Nardi N, King AJF, Jones PM: **Mesenchymal stromal cells improve human islet function through released products and extracellular matrix.** *Clin Sci (Lond)* (2017).
 40. Chen T, Yuan J, Duncanson S, Hibert ML, Kodish BC, Mylavaganam G, Maker M, Li H, Sremac M, Santosuosso M, Forbes B *et al*: **Alginate encapsulant incorporating cxcl12 supports long-term allo- and xenoislet transplantation without systemic immune suppression.** *American Journal of Transplantation* (2015) **15**(3):618-627.
 41. Yazid S, Gardner PJ, Carvalho L, Chu CJ, Flower RJ, Solito E, Lee RW, Ali RR, Dick AD: **Annexin-a1 restricts th17 cells and attenuates the severity of autoimmune disease.** *J Autoimmun* (2015) **58**:1-11.
 42. Gardner PJ, Yazid S, Ribeiro J, Ali RR, Dick AD: **Augmenting endogenous levels of retinal annexin a1 suppresses uveitis in mice.** *Transl Vis Sci Technol* (2017) **6**(5):10.
 43. Sordi V, Melzi R, Mercalli A, Formicola R, Doglioni C, Tiboni F, Ferrari G, Nano R, Chwalek K, Lammert E, Bonifacio E *et al*: **Mesenchymal cells appearing in pancreatic tissue culture are**

bone marrow-derived stem cells with the capacity to improve transplanted islet function. *Stem Cells* (2010) **28**(1):140-151.

44. Kuljanin M, Bell GI, Sherman SE, Lajoie GA, Hess DA: **Proteomic characterisation reveals active wnt-signalling by human multipotent stromal cells as a key regulator of beta cell survival and proliferation.** *Diabetologia* (2017) **60**(10):1987-1998.

*This study aimed to elucidate the secretome of human bone marrow-derived MSCs, with documented islet regenerative paracrine function and highlights the importance of active Wnt signalling in the maintenance of MSC-induced islet regeneration.

45. Wang L, Qing L, Liu H, Liu N, Qiao J, Cui C, He T, Zhao R, Liu F, Yan F, Wang C *et al*: **Mesenchymal stromal cells ameliorate oxidative stress-induced islet endothelium apoptosis and functional impairment via wnt4- β -catenin signaling.** *Stem Cell Res Ther* (2017) **8**(1):188.
46. Rackham CL, Dhadda PK, Chagastelles PC, Simpson SJ, Dattani AA, Bowe JE, Jones PM, King AJ: **Pre-culturing islets with mesenchymal stromal cells using a direct contact configuration is beneficial for transplantation outcome in diabetic mice.** *Cytotherapy* (2013) **15**(4):449-459.
47. Rackham CL, Dhadda PK, Le Lay AM, King AJ, Jones PM: **Preculturing islets with adipose-derived mesenchymal stromal cells is an effective strategy for improving transplantation efficiency at the clinically preferred intraportal site.** *Cell Med* (2014) **7**(1):37-47.
48. Jung EJ, Kim SC, Wee YM, Kim YH, Choi MY: **Bone marrow-derived mesenchymal stromal cells support rat pancreatic islet survival and insulin secretory function in vitro.** *Cytotherapy* (2011).
49. Ki-Soo SP, Young-Seok SK, Jae-Hyeon HK, Bongkum C, Sa-Hyun HK, Alice HT, Myung-Shik SL, Moon-Kyu KL, Choon-Hyuck HK, Jae-Won WJ, Sung-Joo JK *et al*: **Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation.** *Transplantation* (2010) **89**(5):509-517.
50. Yeung TY, Seeberger KL, Kin T, Adesida A, Jomha N, Shapiro AM, Korbitt GS: **Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines.** *PLoS One* (2012) **7**(5):e38189.
51. Montanari E, Meier RPH, Mahou R, Seebach JD, Wandrey C, Gerber-Lemaire S, Buhler LH, Gonelle-Gispert C: **Multipotent mesenchymal stromal cells enhance insulin secretion from human islets via n-cadherin interaction and prolong function of transplanted encapsulated islets in mice.** *Stem Cell Res Ther* (2017) **8**(1):199.
52. Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, Hynes RO: **The extracellular matrix: Tools and insights for the "Omics" Era.** *Matrix Biol* (2016) **49**(10-24).

53. Rondas D, Tomas A, Soto-Ribeiro M, Wehrle-Haller B, Halban PA: **Novel mechanistic link between focal adhesion remodeling and glucose-stimulated insulin secretion.** *J Biol Chem* (2012) **287**(4):2423-2436.
54. Olaniru OE, Pingitore A, Giera S, Piao X, Castañera González R, Jones PM, Persaud SJ: **The adhesion receptor gpr56 is activated by extracellular matrix collagen iii to improve β -cell function.** *Cell Mol Life Sci* (2018).
55. Amisten S, Atanes P, Hawkes R, Ruz-Maldonado I, Liu B, Parandeh F, Zhao M, Huang GC, Salehi A, Persaud SJ: **A comparative analysis of human and mouse islet g-protein coupled receptor expression.** *Sci Rep* (2017) **7**(46600).

** This study demonstrates that islets express an astonishing number of GPCRs (76% of all known non-odrant GPCRs) offering a wide range of targets through which to manipulate islet cell function.

56. Schive SW, Mirlashari MR, Hasvold G, Wang M, Josefsen D, Gullestad HP, Korsgren O, Foss A, Kvalheim G, Scholz H: **Human adipose-derived mesenchymal stem cells respond to short-term hypoxia by secreting factors beneficial for human islets in vitro and potentiate antidiabetic effect in vivo.** *Cell Med* (2017) **9**(3):103-116.
57. Kreutter G, Kassem M, El Habhab A, Baltzinger P, Abbas M, Boisrame-Helms J, Amoura L, Peluso J, Yver B, Fatiha Z, Ubeaud-Sequier G *et al*: **Endothelial microparticles released by activated protein c protect beta cells through epcr/par1 and annexin a1/fpr2 pathways in islets.** *J Cell Mol Med* (2017) **21**(11):2759-2772.
58. Purvis GSD, Chiazza F, Chen J, Azevedo-Loiola R, Martin L, Kusters DHM, Reutelingsperger C, Fountoulakis N, Gnudi L, Yaqoob MM, Collino M *et al*: **Annexin a1 attenuates microvascular complications through restoration of akt signalling in a murine model of type 1 diabetes.** *Diabetologia* (2018) **61**(2):482-495.

*This article demonstrates that prophylactic treatment with recombinant ANXA1 attenuates the development of renal and cardiac dysfunction, whilst therapeutic administration of recombinant ANXA1 halts the further decline of renal and cardiac dysfunction, suggesting ANXA1 to be a potential therapeutic option for the control of secondary complications in diabetes.

59. Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R: **The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration.** *Cytotherapy* (2016) **18**(1):13-24.

**This review provides an overview of our current understanding of the MSC “secretome”; both soluble factors and those released as extracellular vesicles, and the potential clinical applications.

60. Zhi ZL, Singh J, Austin AL, Hope DC, King AJ, Persaud SJ, Jones PM: **Assembly of bioactive multilayered nanocoatings on pancreatic islet cells: Incorporation of α 1-antitrypsin into the coatings.** *Chem Commun (Camb)* (2015) **51**(53):10652-10655.

Pre-Tx delivery of MSC secretory products

Post-Tx delivery of MSC secretory products

(1) Preculture islets with cocktail
of MSC secretory products

Target: Donor islet graft material

(3) Systemic delivery of MSC
secretory products cocktail

Target: Host niche

(2) Co-delivery of MSC secretory
products cocktail

**Target: Donor islet graft material
Host niche**